The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,360 GBX | -0.03% | +1.54% | +16.60% |
22/05 | Behind the numbers: AstraZeneca aims for sales of $80 billion by 2030 | |
22/05 | Stifel Raises AstraZeneca PT, Maintains Buy Rating | MT |
(Reuters) - AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company's initial stage T-cell engager.
The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
1st Jan change | Capi. | |
---|---|---|
+16.60% | 24TCr | |
+37.74% | 72TCr | |
+32.22% | 60TCr | |
-2.07% | 36TCr | |
+20.25% | 33TCr | |
+2.99% | 29TCr | |
+9.77% | 21TCr | |
-5.15% | 21TCr | |
+7.43% | 17TCr | |
+2.81% | 16TCr |